Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10636
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Pittsburgh, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 781–792 of 10,636 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

NCT06616844
View directory record Official record
Conditions
Wound Heal, Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fresno, California • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Completed Phase 3 Interventional Results available

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

NCT03811535
View directory record Official record
Conditions
Growth Hormone Deficiency in Children
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Recruiting Not applicable Interventional

Autologous Fat Grafting Beneath Penile Split Thickness Skin Graft Placement During Penile Reconstruction

NCT07316491
View directory record Official record
Conditions
Penis/Surgery, Penis/Injuries, Penile Skin, Adult-Acquired Buried Penis
Interventions
Autologous fat grafting, Genitourinary Reconstruction with Split-Thickness Skin Grafting
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Recruiting Not applicable Interventional

Effect of Collagen Membrane on Ridge Preservation

NCT07580495
View directory record Official record
Conditions
Dehiscence, Tooth Extraction, Alveolar Bone Loss
Interventions
Minimally Invasive tooth extraction, Alveolar ridge preservation with ABCC, Resorbable collagen membrane (InterCollagen® Guide)
Procedure · Device
Lead sponsor
Debora Dias
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT04420884
View directory record Official record
Conditions
Solid Neoplasms
Interventions
Dazostinag, Pembrolizumab, Platinum, 5-fluorouracil
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Active, not recruiting Phase 1 Interventional

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03952078
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
CPI-818
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Recruiting Phase 3 Interventional

Precision Management of Urinary Tract Symptoms in Older Women

NCT07686055
View directory record Official record
Conditions
Urinary Tract Infection (Diagnosis)
Interventions
Antibiotics
Drug
Lead sponsor
Megan Bradley
Other
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Active, not recruiting No phase listed Observational

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

NCT04142437
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions
larotrectinib(Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
33
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Completed Phase 2 Interventional Results available

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
REC-994, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311
View directory record Official record
Conditions
Gastroesophageal Cancer
Interventions
Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

NCT03698864
View directory record Official record
Conditions
Necrobiosis Lipoidica
Interventions
PCS499
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 15, 2026, 2:54 PM EST